News

Renalytix plc is an LSE AIM listed precision-medicine diagnostics company focused on improving the early identification and management of chronic kidney disease.

Its principal product, KidneyIntelX.dkd, is an AI-enabled blood-based diagnostic that combines biomarkers with patient data to assess an individual’s risk of progressive kidney-function decline. The test has FDA approval and Medicare reimbursement in the US, giving Renalytix a potentially significant commercial opportunity in diabetic kidney disease.

The company is primarily focused on the US market, expanding through physician practices and integration with electronic health-record systems.

Placing, subscription and retail offer

 On 3 September 2026, the Company announced it had conditionally raised gross proceeds of £10.1 million by way of a successful Placing of, and Subscription for, a total of 168,366,151 new Ordinary Shares at the Issue Price of 6 pence.

On 8 September 2026, the Company further announced the completion of the WRAP retail offer at an issue price of £0.06 per Ordinary Share which raised further gross proceeds of £380,142.

Having supported Renalytix with the production of their annual report since 2019, the Perivan shareholder communications team was delighted to work with SP Angel Corporate Finance who acted as Nominated Adviser and Joint Broker on the documentation which was successfully completed and posted to qualifying shareholders on 8 September 2026.

Perivan specialises in producing and publishing financial documents relating to shareholder and investor communications for quoted companies and is a market leader in the production of documentation relating to corporate finance transactions.